Currently out of the existing stock ratings of Julian Harrison, 176 are a BUY (94.62%), 9 are a HOLD (4.84%), 1 are a SELL (0.54%).

Julian Harrison

Work Performance Price Targets & Ratings Chart

Analyst Julian Harrison, currently employed at BTIG, carries an average stock price target met ratio of 39.55% that have a potential upside of 64.43% achieved within 168 days.

Julian Harrison’s has documented 359 price targets and ratings displayed on 32 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on LQDA, Liquidia Technologies at 12-Aug-2026.

Wall Street Analyst Julian Harrison

Analyst best performing recommendations are on AVTE (AEROVATE THERAPEUTICS).
The best stock recommendation documented was for AVTE (AEROVATE THERAPEUTICS) at 12/6/2022. The price target of $27 was fulfilled within 6 days with a profit of $8.97 (49.75%) receiving and performance score of 82.92.

Average potential price target upside

PTGX Protagonist Therapeutics LQDA Liquidia Technologies AVTE Aerovate Therapeutics RXDX Prometheus Biosciences KROS Keros Therapeutics  ACRS Aclaris Therapeutics AXLA Axcella Health VKTX Viking Therapeutics MORF Morphic CBAY Cymabay Therapeu MLTX MoonLake Immunotherapeutics ANAB AnaptysBio OTLK OUTLOOK THERAPEUTICS INC RZLT Rezolute VRDN Viridian Therapeutics TBPH Theravance Biopharma AKBA Akebia Ther ARDX Ardelyx CGEM Cullinan Oncology LLC NKTR Nektar Therapeutics RANI Rani Therapeutics Holdings APGE Apogee Therapeutics, Common Stock AVTX Avalo Therapeutics ABVX Abivax SA American Depositary Shares AVT Avnet INVA Innoviva ORKA Oruka Therapeutics PLRX Pliant Therapeutics  PROG Progenity RNAC Cartesian Therapeutics SYRE Spyre Therapeutics VYNE Vyne Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 05-Dec-2024

$178

$19.38 (12.22%)

$153

Buy Since 08-Sep-2024

$170

$11.38 (7.17%)

$145

Buy Since 04-Nov-2024

$173

$14.38 (9.07%)

$118

Buy Since 16-Jun-2025

$175

$16.38 (10.33%)

$125

Buy Since 25-Aug-2022

$137

$15.12 (12.41%)

$112

Show more analysts

Please expand the browser size to see the chart

Which stock is Julian Harrison is most bullish on?

Potential upside of $104.98 has been obtained for NKTR (NEKTAR THERAPEUTICS)

Which stock is Julian Harrison is most reserved on?

Potential downside of -$0 has been obtained for TBPH (THERAVANCE BIOPHARMA)

What Year was the first public recommendation made by Julian Harrison?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?